Over the years, Leriva has developed an impressive roster of partnerships. These range from distributorship agreements with major multinational and leading international companies to alliances and licensing agreements with smaller companies that are at the forefront of innovation.

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. The company’s Clinical Diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Beckman Coulter’s Life Science research instruments and tools provide analytical solutions and are used by pharmaceutical and biotechnology companies, universities, medical schools, research institutions and a wide range of industries, including food manufacturers and processors. Beckman Coulter is a member of the Danaher family of companies.

SCIEX is a global leader in mass spectrometry and a trusted partner to scientists and lab analysts worldwide. The company’s innovations help protect our environment and our global food supply, advance our understanding of diseases, enable researchers to improve clinical tests, and empower pharmaceutical companies to develop more effective drugs, more quickly and at a lower cost. Sciex is a member of the Danaher group of companies.

Genscript Biotech Corporation, a global biotech company, is a leading life sciences research and application service and product provider that applies its proprietary technology to various fields, from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. By leveraging its proprietary gene synthesis and other technologies, Genscript has established four major platforms. Firstly, a leading contracted research organization (CRO) platform to provide one-stop solutions to global research communities. Secondly, a contract development and manufacturing organization (CDMO) platform. Thirdly, an industrial synthetic products platform. And fourthly, an integrated global cell therapy platform. In response to the Covid-19 pandemic, Genescript launched cPass, a patented novel assay and the first commercially available kit to specifically detect COVID-19 neutralizing antibodies without the use of live virus.

Based in the Netherlands, IQ Products is a privately owned company and a developer, manufacturer and international supplier of a range of antibody-based diagnostic products. The company was founded in cooperation with the University of Groningen in 1987. Flow cytometry is one of the company’s specialties and over the years IQ Products has developed different diagnostic assays to detect rare cell populations, primarily based on high-quality antibodies. Besides flow cytometry, IQ Products also supplies complete kits for enzyme-linked immunosorbent assays (ELISA), hematology analyzers and for fluorescence microscopy tests.

Headquartered in Seoul, South Korea, Seegene is a global pioneer in the field of multi-pathogen testing. Seegene’s innovative and proprietary technologies deliver test results with maximum specificity, reproducibility and sensitivity. The company’s array of molecular diagnostics (MDx) products can detect multiple targets simultaneously, such as viruses and germs that cause respiratory, sexually transmitted infections and cervical cancer. In addition to its array of reagents, Seegene also offers several instrumentation platforms, including automatic detection systems, extraction and auto-electrophoresis instruments, and multiplex and real-time polymerase chain reaction detection systems. Seegene’s solutions are applicable in diverse markets ranging from clinical diagnostics to basic science research.

Founded in 2006 in Austin Texas, Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests.

Based in the UK and formed in 2013 as a spin-out from the Department of Chemistry at the University of Cambridge, Fluidic Analytics designs, develops and manufactures protein characterization tools. The company has developed a new technology for protein analysis that uses microfluidic diffusional sizing to accurately determine the size and concentration of native proteins. This cutting-edge technology enables easier, faster, more convenient and more accurate protein characterization and has broad applications in a multitude of laboratory settings. Fluidic Analytics markets its protein characterization solutions to a wide range of end-users, including clinicians, the biotech and pharma industries, as well as academics.

Founded in 2015 and based in San Francisco in the USA, Loop Genomics has developed long-read DNA sequencing technology which is designed to provide genomics tools that bring clarity to genetic data. The company's technology encompasses consumables and analysis tools that are intended to address a wide range of genetic analysis solutions for research, diagnostics, agricultural biotechnology and industrial applications. Loop’s synthetic read sequencing technology transforms any short-read sequencer into a single molecule long-read sequencer using the laboratory’s existing sequencing hardware.

Autobio Diagnostics, through its R&D efforts and technological innovations, has developed an extensive range of reagents and instruments in the IVD space and has emerged as a leading provider of comprehensive solutions for clinical laboratories across the globe. Since its establishment in 1998, Autobio has been committed to improving laboratory technology and serving human health. Listed on the Shanghai Stock Exchange, the company’s products are available in over 80 countries and encompass application areas such as Immunoassay, Biochemistry and Microbiology. Autobio’s Microbiology offerings include an automated blood culture system which is based on an advanced non-invasive and visualization technology and features a unique optical detection system that facilitates full automation of blood culture testing, and an automated mass spectrometry microbial identification system with a comprehensive spectrum identification platform.

Based in Alabama in the USA, iRepertoire is a pioneer of immune repertoire analysis and was the first to company to develop and commercialize immune repertoire sequencing technology and products. iRepertoire’s products and reagent systems allow researchers to easily and inexpensively generate their own Next Generation Sequencing libraries in the convenience of their laboratory and analyze their data with the company’s proprietary software pipeline. The company’s products are used in clinical and research applications that require immune assessment such as drug treatment monitoring, identification of minimal residual disease (MRD), immune monitoring after stem cell transplantation, vaccine studies, and biomarker development. .

Established in 2004, Taiwan Advanced Nanotech Inc (TANBead) designs and manufactures products for nucleic acid purification, including reagent kits, magnetic nanoparticles, and automated extraction instruments. Based on a solid scientific research foundation, TANBead is committed to creating novel technologies and providing customers with excellent products and professional services. The company has built a fully automatic and truly unique nucleic acid extraction machine for which it has obtained multinational patent affirmation. By creating this excellent nucleic acid extraction experience for users, TANBead has become a global benchmark in the pre-processing system for the analysis of DNA and RNA.

Fresenius Kabi holds leadership positions in the global infusion therapy and clinical nutrition markets and also offers a broad range of intravenously administered generic drugs across a wide array of therapeutic categories. As a leading provider of transfusion technology products used for the collection, processing and transporting of blood products, the company’s product range includes, blood bag and in-line filtration systems, filter systems, devices for cell separation and blood processing equipment.

Bracco is an international group active in the health care sector and a leader in the diagnostic imaging. The group’s main products are contrast agents, medical substances that are classified as pharmaceuticals and are used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying types and severity. The group’s contrast media agents are complemented by several medical devices and advanced administration systems in the fields of cardiology and radiology. Thanks to an extensive and innovative portfolio of products and solutions, the fruit of in-house research, Bracco boasts a leading position in diagnostic imaging at a global level.

Granalix focuses on developing science-based novel formulations of natural antioxidants with increased bioavailability that target specific organs. Based in Israel, Granalix was established in 2014 by a group of scientists as a spinoff of the Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University and Hadasit, the Technology Transfer Company of Hadassah Medical Organization. The company’s flagship product GranaGard is a submicron self-emulsion formulation of Pomegranate Seed Oil (PSO).